{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:04:41Z","timestamp":1777385081406,"version":"3.51.4"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/rlu.0000000000000429","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T02:57:16Z","timestamp":1395716236000},"page":"505-510","source":"Crossref","is-referenced-by-count":29,"title":["Somatostatin Receptor Imaging in Non\u2013131I-Avid Metastatic Differentiated Thyroid Carcinoma for Determining the Feasibility of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE"],"prefix":"10.1097","volume":"39","author":[{"given":"Bhargavi","family":"Jois","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Asopa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandip","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210204","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) Guidelines Task force on Thyroid Nodules and Differentiated Thyroid Cancer.","volume":"19","author":"Cooper","year":"2009","journal-title":"Thyroid"},{"issue":"suppl 1","key":"R2-3-20210204","first-page":"S107","article-title":"Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.","volume":"46","author":"Teunissen","year":"2005","journal-title":"J Nucl Med"},{"key":"R3-3-20210204","doi-asserted-by":"crossref","first-page":"22","DOI":"10.14310\/horm.2002.1150","article-title":"Sodium iodide symporter (NIS) and thyroid.","volume":"1","author":"Spitzweg","year":"2002","journal-title":"Hormones (Athens)"},{"key":"R4-3-20210204","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/erc.1.0978","article-title":"BRAF mutation in thyroid cancer.","volume":"12","author":"Xing","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"R5-3-20210204","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0140-6736(03)12488-9","article-title":"Thyroid carcinoma.","volume":"361","author":"Sherman","year":"2003","journal-title":"Lancet"},{"key":"R6-3-20210204","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1677\/ERC-08-0335","article-title":"New therapeutic advances in the management of progressive thyroid cancer.","volume":"16","author":"Woyach","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"R7-3-20210204","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2184::AID-CNCR21>3.0.CO;2-U","article-title":"131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma.","volume":"78","author":"Sisson","year":"1996","journal-title":"Cancer"},{"key":"R8-3-20210204","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.semnuclmed.2010.10.002","article-title":"The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome.","volume":"41","author":"Silberstein","year":"2011","journal-title":"Semin Nucl Med"},{"key":"R9-3-20210204","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-0029-1243636","article-title":"Somatostatin receptor subtype expression in human thyroid tumours.","volume":"42","author":"Klagge","year":"2010","journal-title":"Horm Metab Res"},{"key":"R10-3-20210204","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/105072501750362718","article-title":"Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer.","volume":"11","author":"Gorges","year":"2001","journal-title":"Thyroid"},{"issue":"suppl 1","key":"R11-3-20210204","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000201391","article-title":"Somatostatin receptor scintigraphy in non-medullary thyroid cancer.","volume":"57","author":"Postema","year":"1996","journal-title":"Digestion"},{"key":"R12-3-20210204","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF03351041","article-title":"Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer.","volume":"24","author":"Haslinghuis","year":"2001","journal-title":"J Endocrinol Invest"},{"key":"R13-3-20210204","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.bjc.6601072","article-title":"Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid.","volume":"89","author":"Christian","year":"2003","journal-title":"Br J Cancer"},{"key":"R14-3-20210204","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00432-003-0435-9","article-title":"Indium-111-octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.","volume":"129","author":"Stokkel","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"key":"R15-3-20210204","first-page":"2018","article-title":"Should the grade of tracer uptake on somatostatin receptor targeted imaging be the major determinant and break the barrier of histopathological criterion for determining suitability of peptide receptor radionuclide therapy J Nucl Med.","volume":"54","author":"Basu","year":"2013","journal-title":""},{"key":"R16-3-20210204","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.","volume":"40","author":"Zaknun","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"suppl 2","key":"R17-3-20210204","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.","volume":"10","author":"Krenning","year":"1999","journal-title":"Ann Oncol"},{"key":"R18-3-20210204","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s00259-013-2501-0","article-title":"Gratifying clinical experience with indigenously formulated single vial lyophilized HYNIC-TOC kit at the Radiopharmaceutical Division of BARC: a pivotal boost for building up a peptide receptor radionuclide therapy programme in an Indian setting.","volume":"40","author":"Basu","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-3-20210204","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.bjc.6690251","article-title":"Expression of somatostatin receptors in oncocytic (Hurthle cell) neoplasia of the thyroid.","volume":"79","author":"Tisell","year":"1999","journal-title":"Br J Cancer"},{"key":"R20-3-20210204","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1089\/thy.1999.9.583","article-title":"Evaluation of indium-111 pentetreotide somato-statin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.","volume":"9","author":"Valli","year":"1999","journal-title":"Thyroid"},{"key":"R21-3-20210204","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/00006231-200106000-00011","article-title":"Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using 90Y-DOTA-D-Phe1-Tyr3-octreotide: a pilot study.","volume":"22","author":"Waldherr","year":"2001","journal-title":"Nucl Med Commun"},{"key":"R22-3-20210204","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/snuc.2002.31565","article-title":"In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.","volume":"32","author":"Virgolini","year":"2002","journal-title":"Semin Nucl Med"},{"key":"R23-3-20210204","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","article-title":"Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptorautoradiography with subtype-selective ligands.","volume":"28","author":"Reubi","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"R24-3-20210204","first-page":"636","article-title":"111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.","volume":"41","author":"Forssell-Aronsson","year":"2000","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000000429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:08:38Z","timestamp":1620972518000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201406000-00003"}},"subtitle":["Low Fraction of Patients Suitable for Peptide Receptor Radionuclide Therapy and Evidence of Chromogranin A Level\u2013Positive Neuroendocrine Differentiation"],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000000429","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}